Foto del docente

Giovanni Brandi

Professore associato confermato

Dipartimento di Scienze Mediche e Chirurgiche

Settore scientifico disciplinare: MED/06 ONCOLOGIA MEDICA

Pubblicazioni

Zeneli A, Brandi G, Di Pasquale G, Orlandini D, De Carolis P, Bravi F, Pugliese F, Poluzzi E, Catena F, Giovanardi F, Valpiani G, Mantovani R, Magnanimi E, Iannone P., Identifying ethical values for guiding triage decisions during the COVID-19 pandemic: an Italian ethical committee perspective using Delphi methodology, «BMJ OPEN», 2021, 11, Article number: e043239, pp. 1 - 10 [articolo]Open Access

Rizzo A.; Ricci A.D.; Brandi G., IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, pp. 1 - 6 [articolo]Open Access

Rizzo A.; Ricci A.D.; Brandi G., Immune-based combinations for advanced hepatocellular carcinoma: Shaping the direction of first-line therapy, «FUTURE ONCOLOGY», 2021, 17, pp. 755 - 757 [articolo]

Rizzo A.; Ricci A.D.; Lanotte L.; Lombardi L.; Di Federico A.; Brandi G.; Gadaleta-Caldarola G., Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 1, pp. 1-9 - 9 [articolo]

Ricci A.D.; Rizzo A.; Brandi G., In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)”, «THE ONCOLOGIST», 2021, 26, pp. e902 - e902 [replica/breve intervento]

Rizzo, A.; Frega, G.; Palloni, A.; Piemontese, A.; Di Federico, A.; Ricci, A.; Carloni, R.; Fabbri, F.; Novelli, M.; Tavolari, S.; Di Marco, M.; Ravaioli, M.; Brandi, G., Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience, «ANNALS OF ONCOLOGY», 2021, 32, Article number: P-69, pp. S120 - S120 [articolo]

Ravaioli M.; Piscaglia F.; Cillo U.; Brandi G.; Sessa M.; Germinario G.; Golfieri R.; Cappelli A.; Morelli M.C.; Siniscalchi A.; D'Errico A.; Cescon M.; Iannone P.; Trevisani F., Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?, «LIVER CANCER», 2021, 10, pp. 394 - 395 [replica/breve intervento]Open Access

Rizzo A.; Ricci A.D.; Brandi G., Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2021, 6, pp. 217 - 224 [articolo]

Rizzo A.; Santoni M.; Mollica V.; Fiorentino M.; Brandi G.; Massari F., Microbiota and prostate cancer, «SEMINARS IN CANCER BIOLOGY», 2021, 1044, pp. 1 - 8 [articolo]

Rizzo A.; Brandi G., Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, Article number: 100354, pp. 100354 - 100360 [articolo]Open Access

Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G., Nivolumab: an investigational agent for the treatment of biliary tract cancer, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 30, pp. 325 - 332 [articolo]

Rizzo A.; Brandi G., Novel targeted therapies for advanced cholangiocarcinoma, «MEDICINA», 2021, 57, Article number: 212, pp. 1 - 3 [articolo]Open Access

Rizzo A.; Ricci A.D.; Brandi G., Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer, «CANCERS», 2021, 13, Article number: 558, pp. 1 - 11 [articolo]Open Access

Rizzo A.; Ricci A.D.; Brandi G., Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, pp. 1 - 6 [articolo]Open Access

Rizzo A.; Brandi G., Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 547 - 554 [articolo]